Skip to content
RDL Network logo
Ipilimumab alone or ipilimumab plus anti-PD-1 therapy in patients with metastatic melanoma resistant to anti-PD-(L)1 monotherapy: a multicentre, retrospective, cohort study — Inês Pires da Silva (2021) | RDL Network